- Email: [email protected]
Immunization of humans against enterotoxogenic infection by Escherichia coli by isolation of E. coli pili and use as vaccine
Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts" with permission of Derwent Publications Ltd.
Immunization of humans against enterotoxogenic infection by Escherichia coli by isolation o f / ~ coli pili and use as vaccine
Bactex US 4,454,116:12 June 1984 Protection of human subjects against colibacillosis caused by a member (A) of a predetermined I st group of strains of piliated Escherichia eol~ by administering to the subject a composition (B) capable of raising the antibody level of the subject to a level sufficient to provide protection against infection caused by (A). (B) Comprises pili separated from other F. co6 strains having type I pili or NMS pili. Cells of the 1st group are agglutinable by serum containing antibodies against pili from the 2nd group. A preferred 1:~ coli strain is H 10407 (ATCC 31703). This strain is grown in a minimal glucose medium, and pili are separated from the cell by blending and centrifugation, in phosphate buffer, pH 7.0. The pili are crystallized from the buffer by the addition of MgCI2, and the purified pili are used to make the vaccine. 001-85
Protection of subject against colibaciliosis, preparation of vaccine containingEscherichia coil type ! or N M S pill
Bactex US 4,454,117; 12 June 1984 Protection against a piliated Fscherichia eoli having type I pili or NMS pili is achieved by administration ofpili derived from a2nd group of strains of piliated £ coli organisms having type I or NMS pili. Cells of the 1st group are agglutinable by serum containing antibodies against pill of the 2nd. The I st group consists of strains that are the same as or different from those of the 2nd group. The E. coli strains are grown on minimal glucose agar base medium, and pili are separated by blending and centrifuging in pH 7.0 phosphate buffer. An MgCI 2 solution is added to crystallize the pili. The pili in a vaccine gave good protection against colibacillosis by raising antibody levels. No local or systemic effects occur after injection of the vaccine. 002-85
Live water fowl salmonellosis vaccine consisting of an aqueous suspension of attenuated Salmonella typhimurium No 3
Immunogenic compositions containing malarial parasite polypeptide extracts for preparation of antimalarial vaccines and in vitro diagnosis of malaria antibodies in serum
lnst Pasteur Eur 112-784, 4 July 1984 An immunogenic composition is described containing one or more malarial parasite polypeptide extract (especially from Plasmodium sp.) characterized by the capacity to react with protective antibodies obtained from monkeys resistant to human malarial parasites. These compositions may be used in the preparation of antimalaria vaccines and in in vitro diagnosis of the presence of malaria antibodies in serum samples. Preferably the polypeptide extracts have a M W between 50 000 and 140 000, induce monkey antibodies active against malarial parasites infectious in humans (e.g. Plasmodium falciparum) and are recognized by serums or other immunoglobulin compositions from animals resistant to the parasite. These extracts are obtained by treatment of the Plasmodium sp. with a detergent solution to dissolve the major part of the cellular structure followed by separation and recovery by e.g. gel-filtration and electrophoresis. The preferred strain o f P falciparum is F U P C 1212. Detailed examples of the preparation, properties and uses of the compositions are given. 004-85 Subunits useful in vaccines for immunization against herpes viral attacks
Merck-USA US 4,452,734; 5 June 1984 An antigenic immunogenic herpes simplex virus 2 (HSV 2) subunit consisting of 3 groups of viral-directed membranebound glycoproteins is described. The subunit is free from D N A and is capable of inducing neutralizing antibody and of being administered as a vaccine. An antigenic immunogenic HSV 1 subunit is also described. The subunits are non-pathogenic and in vaccines they protect the immunized subject against the effects of HSV 1 or 2 both on initial and subsequent challenge. Chick embryos from I 1 day embryonated eggs are trypsinized and the single cell suspension is plated in roller bottles in medium 199 containing fetal calf serum and neomycin and incubated at 36°C. On day 4 the monolayer cultures are infected with HSV 2 and incubated at 34°C on roller mills. The monolayers are extracted with a medium of Triton X-100, NaC1, Tris-HCL phenyl methyl sulphnonyl fluoride (PMSF) and ethanol at 20-23°C. The supernatant after centrifugation is treated with DNase and fractionated on a Lens culinaris lectin affinity column. The viraldirected glycoproteins are characterized. 005-85 Method for the preparation of improved mutant strain of Bordetella bronchiseptica useful as live attenuated vaccine for prophylaxis of R bronchiseptica infection nitrosoguanidine and u.v. irradiation mutagenesis
State-Sci. (ontr. lnst Vet Prep, VeL Inst. water-fowl AU 8290-721:25 May 1984
Nippon- Vaccine US 4,456,588; 26 June 1984
A new vaccine against salmonellosis in water fowl is described and comprises 2-4 billion microbial cells/10 cm 3 concentration of an attenuated strain of Salmonella typhimurium No 3 in drinking water. Preferably the water contains 4-12 wt % saccharose and 0.6-9.0 wt % gelatin to act as preservatives. The vaccine is administered to young water fowl e.g. ducklings and goslings, when they are 3 and 5 days old. Immunity is formed 3-5 days later and persists up to 6 months. The selected organism is grown on a suitable culture medium e.g. Hottinger's broth, for 10-12 h at 37-38°C with aeration. After centrifugation the precipitate obtained is diluted with the preservative medium to 100-120 billion cells/cm 3 concentration, placed in sterile ampoules, freeze-dried and sealed. 003-85
A strain ofBordetella bronchiseptica with hereditary chromosomal markers, being temperature-sensitive and urease-negative, and used in the production of live vaccine, is prepared by subjecting a strain ofB. bronchiseptica to mutagenesis by combined treatment with nitrosoguanidine and u.v. irradiation. The mutant strain grows 32°C but not at 34°C and is urease-negative. It is cultured on a blood agar medium. Cells forming a comparatively small colony are selected and subcultured at least twice to give the desired phase 1 organism with completely capsular antigen and haemolytic activity. Preferably, the starting strain is isolated from the nasal cavity of swine suffering from infectious atroptic rhinitis. The mutant strain, ts-S34.u, has excellent immunity and is very safe. 006-85
Vaccine, Vol. 3, March 1985
73
Immunization of humans against enterotoxogenic infection by Escherichia coli by isolation o f / ~ coli pili and use as vaccine
Bactex US 4,454,116:12 June 1984 Protection of human subjects against colibacillosis caused by a member (A) of a predetermined I st group of strains of piliated Escherichia eol~ by administering to the subject a composition (B) capable of raising the antibody level of the subject to a level sufficient to provide protection against infection caused by (A). (B) Comprises pili separated from other F. co6 strains having type I pili or NMS pili. Cells of the 1st group are agglutinable by serum containing antibodies against pili from the 2nd group. A preferred 1:~ coli strain is H 10407 (ATCC 31703). This strain is grown in a minimal glucose medium, and pili are separated from the cell by blending and centrifugation, in phosphate buffer, pH 7.0. The pili are crystallized from the buffer by the addition of MgCI2, and the purified pili are used to make the vaccine. 001-85
Protection of subject against colibaciliosis, preparation of vaccine containingEscherichia coil type ! or N M S pill
Bactex US 4,454,117; 12 June 1984 Protection against a piliated Fscherichia eoli having type I pili or NMS pili is achieved by administration ofpili derived from a2nd group of strains of piliated £ coli organisms having type I or NMS pili. Cells of the 1st group are agglutinable by serum containing antibodies against pill of the 2nd. The I st group consists of strains that are the same as or different from those of the 2nd group. The E. coli strains are grown on minimal glucose agar base medium, and pili are separated by blending and centrifuging in pH 7.0 phosphate buffer. An MgCI 2 solution is added to crystallize the pili. The pili in a vaccine gave good protection against colibacillosis by raising antibody levels. No local or systemic effects occur after injection of the vaccine. 002-85
Live water fowl salmonellosis vaccine consisting of an aqueous suspension of attenuated Salmonella typhimurium No 3
Immunogenic compositions containing malarial parasite polypeptide extracts for preparation of antimalarial vaccines and in vitro diagnosis of malaria antibodies in serum
lnst Pasteur Eur 112-784, 4 July 1984 An immunogenic composition is described containing one or more malarial parasite polypeptide extract (especially from Plasmodium sp.) characterized by the capacity to react with protective antibodies obtained from monkeys resistant to human malarial parasites. These compositions may be used in the preparation of antimalaria vaccines and in in vitro diagnosis of the presence of malaria antibodies in serum samples. Preferably the polypeptide extracts have a M W between 50 000 and 140 000, induce monkey antibodies active against malarial parasites infectious in humans (e.g. Plasmodium falciparum) and are recognized by serums or other immunoglobulin compositions from animals resistant to the parasite. These extracts are obtained by treatment of the Plasmodium sp. with a detergent solution to dissolve the major part of the cellular structure followed by separation and recovery by e.g. gel-filtration and electrophoresis. The preferred strain o f P falciparum is F U P C 1212. Detailed examples of the preparation, properties and uses of the compositions are given. 004-85 Subunits useful in vaccines for immunization against herpes viral attacks
Merck-USA US 4,452,734; 5 June 1984 An antigenic immunogenic herpes simplex virus 2 (HSV 2) subunit consisting of 3 groups of viral-directed membranebound glycoproteins is described. The subunit is free from D N A and is capable of inducing neutralizing antibody and of being administered as a vaccine. An antigenic immunogenic HSV 1 subunit is also described. The subunits are non-pathogenic and in vaccines they protect the immunized subject against the effects of HSV 1 or 2 both on initial and subsequent challenge. Chick embryos from I 1 day embryonated eggs are trypsinized and the single cell suspension is plated in roller bottles in medium 199 containing fetal calf serum and neomycin and incubated at 36°C. On day 4 the monolayer cultures are infected with HSV 2 and incubated at 34°C on roller mills. The monolayers are extracted with a medium of Triton X-100, NaC1, Tris-HCL phenyl methyl sulphnonyl fluoride (PMSF) and ethanol at 20-23°C. The supernatant after centrifugation is treated with DNase and fractionated on a Lens culinaris lectin affinity column. The viraldirected glycoproteins are characterized. 005-85 Method for the preparation of improved mutant strain of Bordetella bronchiseptica useful as live attenuated vaccine for prophylaxis of R bronchiseptica infection nitrosoguanidine and u.v. irradiation mutagenesis
State-Sci. (ontr. lnst Vet Prep, VeL Inst. water-fowl AU 8290-721:25 May 1984
Nippon- Vaccine US 4,456,588; 26 June 1984
A new vaccine against salmonellosis in water fowl is described and comprises 2-4 billion microbial cells/10 cm 3 concentration of an attenuated strain of Salmonella typhimurium No 3 in drinking water. Preferably the water contains 4-12 wt % saccharose and 0.6-9.0 wt % gelatin to act as preservatives. The vaccine is administered to young water fowl e.g. ducklings and goslings, when they are 3 and 5 days old. Immunity is formed 3-5 days later and persists up to 6 months. The selected organism is grown on a suitable culture medium e.g. Hottinger's broth, for 10-12 h at 37-38°C with aeration. After centrifugation the precipitate obtained is diluted with the preservative medium to 100-120 billion cells/cm 3 concentration, placed in sterile ampoules, freeze-dried and sealed. 003-85
A strain ofBordetella bronchiseptica with hereditary chromosomal markers, being temperature-sensitive and urease-negative, and used in the production of live vaccine, is prepared by subjecting a strain ofB. bronchiseptica to mutagenesis by combined treatment with nitrosoguanidine and u.v. irradiation. The mutant strain grows 32°C but not at 34°C and is urease-negative. It is cultured on a blood agar medium. Cells forming a comparatively small colony are selected and subcultured at least twice to give the desired phase 1 organism with completely capsular antigen and haemolytic activity. Preferably, the starting strain is isolated from the nasal cavity of swine suffering from infectious atroptic rhinitis. The mutant strain, ts-S34.u, has excellent immunity and is very safe. 006-85
Vaccine, Vol. 3, March 1985
73